{"nctId":"NCT02756624","briefTitle":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","startDateStruct":{"date":"2016-04"},"conditions":["Healthy Subjects"],"count":516,"armGroups":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL","interventionNames":["Drug: AC-170 0.24%"]},{"label":"AC-170 Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AC-170 Vehicle"]}],"interventions":[{"name":"AC-170 0.24%","otherNames":[]},{"name":"AC-170 Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* at least 2 years of age\n* be able to self-administer eye drops or have a parent/legal guardian available for this purpose\n* if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)\n* have ocular health within normal limits\n\nExclusion Criteria:\n\n* known contraindications or sensitivities to the study medication or its components\n* any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters\n* use of disallowed medication during the period indicated prior to the enrollment or during the study\n* be pregnant, nursing, or planning a pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% at Visit 1 (Day 1)","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"1.435"},{"groupId":"OG001","value":"0.50","spread":"1.106"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"1.181"},{"groupId":"OG001","value":"0.42","spread":"0.982"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"1.001"},{"groupId":"OG001","value":"0.31","spread":"0.822"}]}]}]},{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% at Visit 2 (Day 8)","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.279"},{"groupId":"OG001","value":"0.19","spread":"0.665"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.872"},{"groupId":"OG001","value":"0.24","spread":"0.766"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.801"},{"groupId":"OG001","value":"0.21","spread":"0.650"}]}]}]},{"type":"PRIMARY","title":"Tolerability of AC 170 0.24% at Visit 3 (Day 22)","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"1.321"},{"groupId":"OG001","value":"0.43","spread":"1.036"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.942"},{"groupId":"OG001","value":"0.25","spread":"0.725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.715"},{"groupId":"OG001","value":"0.14","spread":"0.446"}]}]}]},{"type":"PRIMARY","title":"Number of Treatment Related Adverse Events","description":"Adverse events will be measured through study completion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":343},"commonTop":["Visual acuity reduced","Conjunctival hyperemia","Instillation site pain","Punctate keratitis","Instillation site erythema"]}}}